Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALV NYSE:CS NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVAutoliv$118.91+0.1%$113.07$75.49▼$119.05$9.13B1.39815,987 shs463,072 shsCSCredit Suisse Group$0.89$0.89$0.82▼$6.36$2.77B1.2737.84 million shsN/ATLXTelix Pharmaceuticals$10.99-1.7%$15.23$10.70▼$30.36$3.72BN/A38,700 shs45,682 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVAutoliv+2.41%+4.39%+0.97%+17.91%+22.03%CSCredit Suisse Group0.00%0.00%0.00%0.00%0.00%TLXTelix Pharmaceuticals+3.33%-6.60%-28.20%-31.20%+1,117,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVAutoliv4.1146 of 5 stars2.45.02.50.02.52.52.5CSCredit Suisse GroupN/AN/AN/AN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVAutoliv 2.84Moderate Buy$120.641.46% UpsideCSCredit Suisse Group 0.00N/AN/AN/ATLXTelix Pharmaceuticals 3.00Buy$22.33103.31% UpsideCurrent Analyst Ratings BreakdownLatest TLX, ALV, CS, and MUV2 Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2025ALVAutolivRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$126.00 ➝ $124.007/16/2025ALVAutolivBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.00 ➝ $135.007/11/2025ALVAutolivRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$108.00 ➝ $126.007/9/2025TLXTelix PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform7/3/2025TLXTelix PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.007/2/2025ALVAutolivJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$140.007/1/2025ALVAutolivWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$100.00 ➝ $104.006/25/2025ALVAutolivRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$133.006/12/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.006/5/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$22.005/28/2025ALVAutolivUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$103.00 ➝ $123.00(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVAutoliv$10.39B0.88$13.92 per share8.54$32.29 per share3.68CSCredit Suisse Group$22.88B0.12$0.25 per share3.51$15.26 per share0.06TLXTelix Pharmaceuticals$783.21M4.75$0.12 per share94.75$1.12 per share9.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVAutoliv$647M$9.1413.0110.981.206.83%30.73%8.86%10/17/2025 (Estimated)CSCredit Suisse Group-$7.64B$0.651.37∞N/A15.12%23.83%1.81%N/ATLXTelix Pharmaceuticals$32.93MN/A0.0022.89N/AN/AN/AN/A8/20/2025 (Estimated)Latest TLX, ALV, CS, and MUV2 EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/20/2025H1 2025TLXTelix Pharmaceuticals$0.2160N/AN/AN/A$316.69 millionN/A7/18/2025Q2 2025ALVAutoliv$2.07$2.21+$0.14$2.16$2.57 billion$2.71 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVAutoliv$2.802.35%N/A30.63%1 YearsCSCredit Suisse Group$0.055.62%N/A7.69%N/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ALatest TLX, ALV, CS, and MUV2 DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/4/2025ALVAutolivquarterly$0.853.31%9/5/20259/5/20259/23/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVAutoliv0.550.930.70CSCredit Suisse Group2.791.531.53TLXTelix Pharmaceuticals0.992.782.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVAutoliv69.57%CSCredit Suisse Group11.20%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipALVAutoliv0.20%CSCredit Suisse GroupN/ATLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVAutoliv65,20076.81 million76.65 millionOptionableCSCredit Suisse Group50,4803.11 billionN/AOptionableTLXTelix PharmaceuticalsN/A338.40 millionN/AN/ATLX, ALV, CS, and MUV2 HeadlinesRecent News About These CompaniesTelix Pharmaceuticals (TLX) Projected to Post Earnings on WednesdayAugust 14 at 2:36 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLXAugust 13 at 11:15 AM | globenewswire.comTelix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena – Hagens BermanAugust 12 at 1:16 PM | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year Low - Time to Sell?August 12 at 11:09 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLXAugust 11 at 10:00 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLXAugust 9, 2025 | globenewswire.comTelix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens BermanAugust 8, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Time to Buy?August 7, 2025 | marketbeat.comABC Arbitrage SA Takes Position in Telix Pharmaceuticals Limited (NASDAQ:TLX)August 7, 2025 | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's WhyAugust 6, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLXAugust 6, 2025 | prnewswire.comBroker says Telix shares could surge 80% higher after selloffAugust 5, 2025 | msn.comTelix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens BermanAugust 5, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Reaches New 52-Week Low - Should You Sell?August 5, 2025 | marketbeat.comTLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law FirmJuly 31, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLXJuly 31, 2025 | prnewswire.comTelix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens BermanJuly 31, 2025 | prnewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year Low - Should You Sell?July 30, 2025 | marketbeat.comTelix H1 2025 Results: Investor Webcast NotificationJuly 29, 2025 | globenewswire.comTelix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens BermanJuly 29, 2025 | globenewswire.comTelix Pharmaceuticals: Assessing The Market's Pullback On SEC InquiryJuly 29, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGolden Cross Alert: 3 Stocks With Serious Upside PotentialBy Chris Markoch | July 31, 20253 High-Risk, High-Reward Stocks With Explosive UpsideBy Nathan Reiff | July 16, 2025Palantir Bulls and Bears Set for an August Showdown By Chris Markoch | July 22, 20253 Bullish Biotech Stocks With Explosive Growth TrendsBy Chris Markoch | July 21, 2025CSX Stock Rally: Strong Options Flow, Analyst Price TargetsBy Jeffrey Neal Johnson | July 18, 2025TLX, ALV, CS, and MUV2 Company DescriptionsAutoliv NYSE:ALV$118.91 +0.10 (+0.08%) Closing price 03:59 PM EasternExtended Trading$118.94 +0.04 (+0.03%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autoliv, Inc., through its subsidiaries, develops, manufactures, and supplies passive safety systems to the automotive industry in Europe, the Americas, China, Japan, and rest of Asia. It offers passive safety systems, including modules and components for frontal-impact airbag protection systems, side-impact airbag protection systems, seatbelts, steering wheels, and inflator technologies. The company also provides mobility safety solutions, such as pedestrian protection, battery cut-off switches, connected safety services, and safety solutions for riders of powered two wheelers. It primarily serves car manufacturers. Autoliv, Inc. was founded in 1953 and is headquartered in Stockholm, Sweden.Credit Suisse Group NYSE:CS$0.89 0.00 (0.00%) As of 06/13/2023Credit Suisse Group AG is a holding company, which engages in the provision of financial services. It operates through the following four divisions: Wealth Management, Investment Bank, Swiss Bank and Asset Management and four geographic regions: Switzerland, Europe, the Middle East and Africa (EMEA), Asia Pacific, and Americas. The Wealth Management division offers comprehensive wealth management and investment solutions, tailored financing, and advisory services to ultra-high-net-worth (UHNW) and high net-worth (HNW) individuals and external asset managers. The Investment Bank division offers a broad range of financial products and services focused on client-driven businesses and also supports Credit Suisse's Wealth Management division and its clients. The Swiss Bank division offers comprehensive advice and a wide range of financial solutions to private, corporate, and institutional clients in Switzerland. The Asset Management division offers investment solutions and services globally to a broad range of clients, including pension funds, governments, foundations and endowments, corporations, and individuals. The company was founded by Alfred Escher on July 5, 1856 and is headquaTelix Pharmaceuticals NASDAQ:TLX$10.98 -0.20 (-1.74%) Closing price 03:58 PM EasternExtended Trading$11.04 +0.05 (+0.50%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Brinker Serves Up Earnings Beat, Sidesteps Cost Pressures CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests 5 Stocks Insiders Are Selling That Analysts Say Buy CoreWeave Pulls Back Into a Screaming Buy Amazon’s Bears Have Raised the White Flag—Get Excited Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access